Anteris Technologies (ASX:AVR) Risk Assessment

View and export this data going back to 2004. Start your Free Trial

What is Anteris Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Anteris Technologies is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Anteris Technologies's Risk Assessment

For the Medical Devices subindustry, Anteris Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anteris Technologies's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's Risk Assessment falls into.

Anteris Technologies (ASX:AVR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Anteris Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies (ASX:AVR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (ASX:AVR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

AMEUF:USA

Address

Level 3, 9 Sherwood Road, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066

Website

https://www.anteristech.com

Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.

Anteris Technologies (ASX:AVR) Headlines

No Headlines